Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 11
1999 14
2000 16
2001 27
2002 37
2003 45
2004 55
2005 50
2006 80
2007 69
2008 41
2009 72
2010 77
2011 83
2012 78
2013 71
2014 92
2015 73
2016 89
2017 76
2018 82
2019 94
2020 87
2021 120
2022 109
2023 99
2024 105
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,671 results

Results by year

Filters applied: . Clear all
Page 1
CCL19-producing fibroblasts promote tertiary lymphoid structure formation enhancing anti-tumor IgG response in colorectal cancer liver metastasis.
Zhang Y, Liu G, Zeng Q, Wu W, Lei K, Zhang C, Tang M, Zhang Y, Xiang X, Tan L, Cui R, Qin S, Song X, Yin C, Chen Z, Kuang M. Zhang Y, et al. Cancer Cell. 2024 Aug 12;42(8):1370-1385.e9. doi: 10.1016/j.ccell.2024.07.006. Cancer Cell. 2024. PMID: 39137726
We identify a fibroblast lineage secreting CCL19 that facilitates lymphocyte trafficking to TLSs. CCL19 treatment promotes TLS neogenesis and prevents tumor growth in mice. Our data uncover the central role of CCL19(+) fibroblasts in TLS formation, which in t …
We identify a fibroblast lineage secreting CCL19 that facilitates lymphocyte trafficking to TLSs. CCL19 treatment promotes TLS …
IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin.
Pang N, Shi J, Qin L, Chen A, Tang Y, Yang H, Huang Y, Wu Q, Li X, He B, Li T, Liang B, Zhang J, Cao B, Liu M, Feng Y, Ye X, Chen X, Wang L, Tian Y, Li H, Li J, Hu H, He J, Hu Y, Zhi C, Tang Z, Gong Y, Xu F, Xu L, Fan W, Zhao M, Chen D, Lian H, Yang L, Li P, Zhang Z. Pang N, et al. J Hematol Oncol. 2021 Jul 29;14(1):118. doi: 10.1186/s13045-021-01128-9. J Hematol Oncol. 2021. PMID: 34325726 Free PMC article. Clinical Trial.
Although chimeric antigen receptor (CAR)-engineered T cells have shown great success in the treatment of B cell malignancies, this strategy has limited efficacy in patients with solid tumors. In mouse CAR-T cells, IL-7 and CCL19 expression have been demonstrated to improve …
Although chimeric antigen receptor (CAR)-engineered T cells have shown great success in the treatment of B cell malignancies, this strategy …
Does CCL19 act as a double-edged sword in cancer development?
Gowhari Shabgah A, Al-Obaidi ZMJ, Sulaiman Rahman H, Kamal Abdelbasset W, Suksatan W, Bokov DO, Thangavelu L, Turki Jalil A, Jadidi-Niaragh F, Mohammadi H, Mashayekhi K, Gholizadeh Navashenaq J. Gowhari Shabgah A, et al. Clin Exp Immunol. 2022 Apr 4;207(2):164-175. doi: 10.1093/cei/uxab039. Clin Exp Immunol. 2022. PMID: 35020885 Free PMC article. Review.
Through the induction of anti-tumor immune responses and inhibition of angiogenesis, CCL19 exerts tumor-suppressive functions. In contrast, CCL19 also acts as a tumor-supportive factor by inducing inflammation, cell growth, and metastasis. ...Using CCL19-base …
Through the induction of anti-tumor immune responses and inhibition of angiogenesis, CCL19 exerts tumor-suppressive functions. In con …
IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor.
Adachi K, Kano Y, Nagai T, Okuyama N, Sakoda Y, Tamada K. Adachi K, et al. Nat Biotechnol. 2018 Apr;36(4):346-351. doi: 10.1038/nbt.4086. Epub 2018 Mar 5. Nat Biotechnol. 2018. PMID: 29505028
We engineered CAR-T cells to express interleukin (IL)-7 and CCL19 (7 19 CAR-T cells), as these factors are essential for the maintenance of T-cell zones in lymphoid organs. ...
We engineered CAR-T cells to express interleukin (IL)-7 and CCL19 (7 19 CAR-T cells), as these factors are essential for the maintena …
GPC3-IL7-CCL19-CAR-T primes immune microenvironment reconstitution for hepatocellular carcinoma therapy.
Lu LL, Xiao SX, Lin ZY, Bai JJ, Li W, Song ZQ, Zhou YH, Lu B, Wu WZ. Lu LL, et al. Cell Biol Toxicol. 2023 Dec;39(6):3101-3119. doi: 10.1007/s10565-023-09821-w. Epub 2023 Oct 19. Cell Biol Toxicol. 2023. PMID: 37853185
Novel GPC3-7-19-CAR-T cells designed with mediate level of IL-7 secretion and high level of CCL19 secretion, which could recruit more mature DCs to assist killing on GPC3(+)HCCs. ...Compared with conventional GPC3-CAR-T, GPC3-7-CCL19-CAR-T cells could reverse tumor …
Novel GPC3-7-19-CAR-T cells designed with mediate level of IL-7 secretion and high level of CCL19 secretion, which could recruit more …
CCL19(+) dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer.
Wu SY, Zhang SW, Ma D, Xiao Y, Liu Y, Chen L, Song XQ, Ma XY, Xu Y, Chai WJ, Jin X, Shao ZM, Jiang YZ. Wu SY, et al. Med. 2023 Jun 9;4(6):373-393.e8. doi: 10.1016/j.medj.2023.04.008. Epub 2023 May 17. Med. 2023. PMID: 37201522 Free article.
These cells were correlated with antitumor T cell immunity and the presence of tertiary lymphoid structures and lymphoid aggregates, defining immunogenic microenvironments in triple-negative breast cancer. In vivo, CCL19(+) DC deletion by Ccl19 gene ablation dampene …
These cells were correlated with antitumor T cell immunity and the presence of tertiary lymphoid structures and lymphoid aggregates, definin …
CCL19 and CCR7 Expression, Signaling Pathways, and Adjuvant Functions in Viral Infection and Prevention.
Yan Y, Chen R, Wang X, Hu K, Huang L, Lu M, Hu Q. Yan Y, et al. Front Cell Dev Biol. 2019 Oct 1;7:212. doi: 10.3389/fcell.2019.00212. eCollection 2019. Front Cell Dev Biol. 2019. PMID: 31632965 Free PMC article. Review.
Chemokine (C-C motif) ligand 19 (CCL19) is a critical regulator of the induction of T cell activation, immune tolerance, and inflammatory responses during continuous immune surveillance, homeostasis, and development. ...In this review, we summarize the impacts of CCL19 …
Chemokine (C-C motif) ligand 19 (CCL19) is a critical regulator of the induction of T cell activation, immune tolerance, and inflamma …
Development of Nectin4/FAP-targeted CAR-T cells secreting IL-7, CCL19, and IL-12 for malignant solid tumors.
Li F, Zhao S, Wei C, Hu Y, Xu T, Xin X, Zhu T, Shang L, Ke S, Zhou J, Xu X, Gao Y, Zhao A, Gao J. Li F, et al. Front Immunol. 2022 Nov 21;13:958082. doi: 10.3389/fimmu.2022.958082. eCollection 2022. Front Immunol. 2022. PMID: 36479116 Free PMC article.
Then, we found that our fourth-generation Nectin4-7.19 CAR-T cells expressed IL-7 and CCL19 efficiently and exhibited superior proliferation, migration, and cytotoxicity compared to the second-generation Nectin4 CAR-T cells, while FAP-12 CAR-T cells exerted their ability o …
Then, we found that our fourth-generation Nectin4-7.19 CAR-T cells expressed IL-7 and CCL19 efficiently and exhibited superior prolif …
Chemokine CCL19 promotes type 2 T-cell differentiation and allergic airway inflammation.
Nakano K, Whitehead GS, Lyons-Cohen MR, Grimm SA, Wilkinson CL, Izumi G, Livraghi-Butrico A, Cook DN, Nakano H. Nakano K, et al. J Allergy Clin Immunol. 2024 Feb;153(2):487-502.e9. doi: 10.1016/j.jaci.2023.10.024. Epub 2023 Nov 11. J Allergy Clin Immunol. 2024. PMID: 37956733
However, is has been unclear whether the other CCR7 ligand, CCL19, has a role in allergic airway disease. OBJECTIVE: This study sought to define the role of CCL19 in T(H)2 differentiation and allergic airway disease. METHODS: Ccl19-deficient mice were studied …
However, is has been unclear whether the other CCR7 ligand, CCL19, has a role in allergic airway disease. OBJECTIVE: This study sough …
CCL19: a novel prognostic chemokine modulates the tumor immune microenvironment and outcomes of cancers.
Gu Q, Zhou S, Chen C, Wang Z, Xu W, Zhang J, Wei S, Yang J, Chen H. Gu Q, et al. Aging (Albany NY). 2023 Nov 8;15(21):12369-12387. doi: 10.18632/aging.205184. Epub 2023 Nov 8. Aging (Albany NY). 2023. PMID: 37944262 Free PMC article.
RESULTS: Based on large-scale multi-center survival analysis of cancer patients, we found the prognosis of patients with high CCL19 expression was prominently better than those with low CCL19 expression. For patients from multiple independent cohorts, suppressed …
RESULTS: Based on large-scale multi-center survival analysis of cancer patients, we found the prognosis of patients with high CCL19 e …
1,671 results